https://recursion.com https://recursion.com/pipeline https://recursion.com/our-story https://recursion.com/blogs https://recursion.com/press https://recursion.com/nda https://recursion.com/team https://recursion.com/expanded-access-policy https://recursion.com/esg https://recursion.com/careers https://recursion.com/scientificmaterials https://recursion.com/rsvp-no https://recursion.com/rsvp-yes https://recursion.com/rsvp-thank-you https://recursion.com/partners https://recursion.com/terms-of-use https://recursion.com/privacy-notice https://recursion.com/privacy-notice-research-participants https://recursion.com/privacy-notice-study-site-personnel https://recursion.com/vendor-expectations-and-resources https://recursion.com/download-day https://recursion.com/clinical-trial-transparency https://recursion.com/msci-disclaimer https://recursion.com/sustainalytics-disclaimer https://recursion.com/yearbook/2013-2014 https://recursion.com/yearbook/2015 https://recursion.com/yearbook/2016 https://recursion.com/yearbook/2017 https://recursion.com/yearbook/2018 https://recursion.com/yearbook/2019 https://recursion.com/yearbook/2020 https://recursion.com/yearbook/2021 https://recursion.com/yearbook/2022 https://recursion.com/yearbook/2023 https://recursion.com/yearbook/toc https://recursion.com/lowe https://recursion.com/open-positions https://recursion.com/recursion-decoded https://recursion.com/accessibility https://recursion.com/media-kit https://recursion.com/mission https://recursion.com/platform https://recursion.com/faq https://recursion.com/yearbook/2024 https://recursion.com/clinical-trials https://recursion.com/clinical-trials/familial-adenomatous-polyposis-clinical-trial https://recursion.com/clinical-trials/familial-adenomatous-polyposis-thank-you https://recursion.com/careers/exec-director-rare https://recursion.com/careers/srsci-sep https://recursion.com/careers/techbiodisco https://recursion.com/team-members/ben-mabey https://recursion.com/team-members/ben-taylor https://recursion.com/team-members/blake-borgeson https://recursion.com/team-members/chris-gibson https://recursion.com/team-members/david-hallett https://recursion.com/team-members/dean-li https://recursion.com/team-members/elaine-sun https://recursion.com/team-members/erica-fox https://recursion.com/team-members/franziska-michor https://recursion.com/team-members/manny-cardenas https://recursion.com/team-members/matt-kinn https://recursion.com/team-members/najat-khan https://recursion.com/team-members/namandje-bumpus https://recursion.com/team-members/nathan-hatfield https://recursion.com/team-members/robert-hershberg https://recursion.com/team-members/ryan-kelly https://recursion.com/team-members/sid-jain https://recursion.com/team-members/vicki-goodman-m-d https://recursion.com/team-members/zachary-bogue https://recursion.com/team-members/zavain-dar https://recursion.com/news/2025s-fiercest-women-in-life-sciences https://recursion.com/news/90-days-as-a-recursionaut https://recursion.com/news/a-computer-scientists-quest-for-meaningful-work https://recursion.com/news/a-new-phenotypic-lexicon-for-accelerated-translation https://recursion.com/news/a-phenomics-platform-combining-imaging-and-artificial-intelligence-for-rapid-validation-and-advancement-of-novel-oncology-targets https://recursion.com/news/a-technique-called-cell-painting-could-speed-drug-discovery https://recursion.com/news/accelerating-ai-drug-discovery-with-open-source-datasets https://recursion.com/news/active-learning-on-synthons-for-molecular-design-salsa https://recursion.com/news/admet-predictions-get-ai-boost-federated-data-network-unites-pharma https://recursion.com/news/after-a-tough-year-exscientia-folds-into-recursion-to-create-an-ai-superpower https://recursion.com/news/ai-driven-discovery-and-profiling-of-gtaexs617-a-selective-and-highly-potent-inhibitor-of-cdk7 https://recursion.com/news/ai-driven-drug-discovery-picks-up-as-fda-pushes-to-reduce-animal-testing https://recursion.com/news/ai-drug-developers-recursion-exscientia-to-merge https://recursion.com/news/ai-machine-learning https://recursion.com/news/ai-medicines-are-coming https://recursion.com/news/ai-use-in-repurposing-drugs-for-covid-19 https://recursion.com/news/ais-drug-revolution-part-2-new-uses-for-old-drugs https://recursion.com/news/altitude-lab-launches-investor-coalition-to-fund-and-mentor-healthcare-startups-in-utah https://recursion.com/news/amelioration-of-osteomalacia-in-late-onset-hpp-mice-via-pharmacological-inhibition-of-enpp1 https://recursion.com/news/an-exciting-milestone-in-our-partnership-with-roche-and-genentech https://recursion.com/news/artificial-intelligence-reveals-protein-dna-interactions https://recursion.com/news/assessing-interaction-recovery-of-predicted-protein-ligand-poses https://recursion.com/news/automated-design-of-kinase-inhibitors-using-alphafold2-models https://recursion.com/news/automating-structure-based-design-integrating-fragment-hotspot-maps-in-drug-discovery-pipelines-at-scale https://recursion.com/news/backed-by-recursion-ceo-altitude-lab-venture-aims-to-fill-gap-from-nih-cuts https://recursion.com/news/bayer-partnership https://recursion.com/news/bet-on-the-big-idea---the-only-way-to-change-the-world https://recursion.com/news/beyond-boltz-2-toward-more-powerful-drug-discovery-tools https://recursion.com/news/beyond-the-deal-recursions-transformational-partnership-with-roche-and-genentech https://recursion.com/news/biological-cartography-building-and-benchmarking-representations-of-life https://recursion.com/news/biotech-firm-recursion-to-buy-smaller-peer-exscientia-for-688-million https://recursion.com/news/boltz-2-towards-accurate-and-efficient-binding-affinity-prediction https://recursion.com/news/boltz-abfe-free-energy-perturbation-without-crystal-structures https://recursion.com/news/bridging-ai-driven-design-and-lab-automation-for-accelerated-drug-discovery https://recursion.com/news/brightfield-is-back-a-17th-century-cell-imaging-technique-is-making-a-comeback-thanks-to-machine-learning https://recursion.com/news/building-benchmarking-and-exploring-perturbative-maps-of-transcriptional-and-morphological-data https://recursion.com/news/building-benchmarking-and-exploring-perturbative-maps-of-transcriptional-and-morphological-data-2 https://recursion.com/news/building-better-cancer-drugs-can-ai-shift-the-odds https://recursion.com/news/cell-painting-a-high-content-image-based-assay-for-morphological-profiling-using-multiplexed-fluorescent-dyes-2 https://recursion.com/news/cellneighbor-a-transcriptional-atlas-of-patient-tumors-and-cell-line-models-to-inform-preclinical-model-selection https://recursion.com/news/characterisation-of-exs73565-a-potent-and-selective-malt1-inhibitor-with-low-drug-drug-interaction-risk-and-potential-in-lymphoma https://recursion.com/news/characterization-and-comparison-of-inhibitors-of-gpr68 https://recursion.com/news/characterizing-antitumor-responses-to-exs74539-a-novel-reversible-lsd1-inhibitor-with-potential-in-small-cell-lung-cancer https://recursion.com/news/chavez-burrell-join-recursions-board-of-directors https://recursion.com/news/chris-gibson-discusses-combination-deal-with-exscientia-on-bloomberg-the-close https://recursion.com/news/chris-gibson-on-industrializing-drug-discovery https://recursion.com/news/chutes-ladders--recursion-makes-big-executive-splash-nabs-j-js-chief-data-science-officer https://recursion.com/news/clinical-trials-get-a-council-for-ai-oversight https://recursion.com/news/companies-are-gaining-an-edge-during-the-great-resignation-by-doing-more-to-help-parents-through-the-chaos-years https://recursion.com/news/computer-aided-biology-cab-doe-solutions https://recursion.com/news/computer-vision-based-digital-biomarkers-could-enable-faster-and-more-accurate-in-vivo-assessment-of-disease https://recursion.com/news/creating-an-ai-first-drug-discovery-engine https://recursion.com/news/delivering-the-worlds-first-neuromap https://recursion.com/news/democratizing-artificial-intelligence-in-pre-clinical-drug-discovery https://recursion.com/news/demystifying-protein-structure-prediction-models-alphafold-rosettafold-esmfold-and-beyond https://recursion.com/news/discovery-of-a-novel-dcaf1-ligand-using-a-drug-target-interaction-prediction-model-generalizing-machine-learning-to-new-drug-targets https://recursion.com/news/dr-robert-hershberg-joins-recursions-board-of-directors https://recursion.com/news/drug-discovery-on-the-dark-proteome-delivering-tomorrows-medicines https://recursion.com/news/drug-discovery-stat-nvidia-recursion-speed-pharma-r-d-with-ai-supercomputer https://recursion.com/news/effective-biological-representation-learning-by-masking-gene-expression https://recursion.com/news/enpp1-inhibition-as-a-therapeutic-approach-for-later-onset-hypophosphatasia https://recursion.com/news/failing-fast-new-and-strategic-ways-to-prune-your-portfolio https://recursion.com/news/first-in-class-inhibitors-of-the-proton-sensing-receptor-gpr68-for-oncology https://recursion.com/news/fragment-hotspot-mapping-to-identify-selectivity-determining-regions-between-related-proteins https://recursion.com/news/from-novel-discovery-to-precision-biomarkers-how-recursion-is-using-data-and-ai-to-deliver-new-cancer-drugs https://recursion.com/news/from-promise-to-practice-danaher-gathers-visionaries-to-discuss-ai-driven-r-d https://recursion.com/news/full-transcript-of-recursions-fourth-quarter-year-end-2025-earnings-call https://recursion.com/news/functional-immune-mapping-with-deep-learning-enabled-phenomics-applied-to-immunomodulatory-and-covid-19-drug-discovery https://recursion.com/news/generative-design-using-active-learning-over-synthon-space https://recursion.com/news/google-cloud-dexcom-and-recursion-see-ai-agents-shifting-from-demo-to-practical-lab-applications https://recursion.com/news/gratitude-at-recursion https://recursion.com/news/hack-week https://recursion.com/news/hands-off-screening-with-cells-automation-of-a-cellular-biosensor-to-facilitate-efficient-hit-compound-screening https://recursion.com/news/harnessing-the-power-of-ai https://recursion.com/news/high-resolution-genome-wide-mapping-of-chromosome-arm-scale-truncations-induced-by-crispr-cas9-editing-2 https://recursion.com/news/how-a-first-of-its-kind-microglia-map-from-recursion-and-roche-and-genentech-could-unlock-new-treatments-for-neurodegenerative-diseases https://recursion.com/news/how-phenomic-foundation-models-are-empowering-the-brightfield-comeback https://recursion.com/news/how-public-data-fuels-the-next-wave-of-drug-innovation https://recursion.com/news/how-recursion-hopes-to-harness-the-big-picture-view-to-understand-biologys-landscape https://recursion.com/news/how-recursion-invests-in-developer-experience https://recursion.com/news/how-recursion-is-empowering-women-leaders-in-utah-and-beyond https://recursion.com/news/hq-expansion-2023-robot-showcase-murals https://recursion.com/news/identification-and-optimization-of-novel-small-molecule-modulators-of-immune-checkpoint-resistance-with-a-unified-representation-space-for-genomic-and-chemical-perturbations https://recursion.com/news/identification-of-potential-treatments-for-covid-19-through-artificial-intelligence-enabled-phenomic-analysis-of-human-cells-infected-with-sars-cov-2 https://recursion.com/news/improving-assay-optimisation-and-pharmacological-sensitivity-of-a-nuclease-by-employing-a-computer-aided-biology-approach https://recursion.com/news/improving-generalisability-of-3d-binding-affinity-models-in-low-data-regimes https://recursion.com/news/improving-wet-lab-automation-with-computer-vision-a-hack-week-breakthrough https://recursion.com/news/innovationrx-recursion-launches-fund-for-biotech-startups-hit-by-nih-funding-cuts https://recursion.com/news/innovationrx-recursions-ceo-talks-clinical-trial-data-for-ai-designed-drug https://recursion.com/news/internship-reflection https://recursion.com/news/introducing-mole-a-new-model-for-predicting-molecular-properties-for-ai-drug-design-and-beyond https://recursion.com/news/investors-want-proof-ai-will-aid-drug-discovery-evidence-may-come-in-the-second-half https://recursion.com/news/key-takeaways-from-bio-2022-for-ai-enabled-drug-discovery https://recursion.com/news/leadership-evolution-passing-the-baton-to-win-the-race https://recursion.com/news/learning-the-effects-of-molecules-on-cells-with-molphenix https://recursion.com/news/leveraging-the-power-of-patient-data-in-ai-drug-discovery https://recursion.com/news/mapping-biology-with-a-unified-representation-space-for-genomic-and-chemical-perturbations-to-enable-accelerated-drug-discovery https://recursion.com/news/maps-of-biology---and-benchmarks---for-all https://recursion.com/news/masked-autoencoders-are-scalable-learners-of-cellular-morphology https://recursion.com/news/masked-autoencoders-for-microscopy-are-scalable-learners-of-cellular-biology https://recursion.com/news/mit-and-recursion-launch-an-open-source-protein-co-folding-model-accelerated-by-nvidia https://recursion.com/news/mit-and-recursion-partner-for-ai-drug-discovery-tool https://recursion.com/news/modeling-animal-data-for-more-efficient-ai-drug-discovery https://recursion.com/news/mole-a-foundation-model-for-molecular-graphs-using-disentangled-attention https://recursion.com/news/mole-a-molecular-foundation-model-for-drug-discovery https://recursion.com/news/multi-objective-gflownets https://recursion.com/news/najat-khan-phd-on-the-techbio-movement https://recursion.com/news/new-computational-methods-for-the-early-characterisation-of-drug-induced-liver-toxicity https://recursion.com/news/new-datas-not-enough-how-recursion-is-integrating-data-layers-to-advance-end-to-end-drug-discovery https://recursion.com/news/nothing-short-of-phenomenal-new-deep-learning-model-available-on-nvidias-bionemo-platform https://recursion.com/news/nvidia-deepens-bets-on-ai-in-drug-discovery-with-recursion-investment https://recursion.com/news/obtaining-cellular-morphological-embeddings-across-experimental-batches https://recursion.com/news/ongoing-phase-1b-2-trial-of-the-allosteric-mek1-2-inhibitor-rec-4881-as-monotherapy-in-familial-adenomatous-polyposis-fap https://recursion.com/news/overcoming-traditional-design-limitations-with-ai-based-discovery-rec-617-interim-phase-1-monotherapy-dose-escalation-clinical-data https://recursion.com/news/painting-the-picture-of-recursion-anne-carpenter-scientific-advisory-board-member https://recursion.com/news/patience-is-all-you-need-an-agentic-system-for-performing-scientific-literature-review https://recursion.com/news/pursuit-of-novel-first-in-class-medicines-with-a-suite-of-ai-enabled-platform-technologies https://recursion.com/news/putting-patients-first-with-medical-ai https://recursion.com/news/r-martin-chavez-appointed-chairman-of-recursions-board-of-directors https://recursion.com/news/rebranding-repurposing-a-polypharmacological-perspective https://recursion.com/news/rec-4881 https://recursion.com/news/recursion-acquires-two-ai-based-drug-discovery-companies-in-87-5m-deal https://recursion.com/news/recursion-acquires-vium-bolstering-its-efforts-to-industrialize-drug-discovery https://recursion.com/news/recursion-advances-ai-based-c-diff-candidate-to-phase-ii https://recursion.com/news/recursion-and-bayer-expand-fibrosis-collaboration-to-include-inferential-search-capabilities https://recursion.com/news/recursion-and-google-cloud-announce-expansion-of-partnership-to-support-drug-discovery-with-cloud-and-exploration-of-generative-ai-technologies https://recursion.com/news/recursion-announces-150-million-private-placement-to-new-and-existing-investors-led-by-kinnevik-ab https://recursion.com/news/recursion-announces-enrollment-of-first-patient-in-phase-2-trial-for-the-treatment-of-cerebral-cavernous-malformation https://recursion.com/news/recursion-announces-first-internally-developed-nce-advanced-to-ind-enabling-studies-to-potentially-treat-clostridium-difficile-colitis https://recursion.com/news/recursion-announces-initiation-of-phase-2-3-trial-for-the-treatment-of-nf2-mutated-meningiomas-at-children-s-tumor-foundation-nf-conference https://recursion.com/news/recursion-announces-its-first-major-multidisciplinary-expansion-in-toronto-to-further-tech-enabled-drug-discovery https://recursion.com/news/recursion-announces-multi-year-collaboration-with-mila-for-tech-enabled-drug-discovery https://recursion.com/news/recursion-announces-new-generative-ai-platform-to-speed-up-drug-discovery https://recursion.com/news/recursion-announces-therapeutics-advisory-board-chaired-by-joseph-miletich-md-phd https://recursion.com/news/recursion-announces-transformational-collaboration-with-roche-and-genentech-in-neuroscience-and-oncology-advancing-novel-medicines-to-patients-using-machine-learning-and-high-content-screening-methods-at-scale-to-map-complex-biology https://recursion.com/news/recursion-appoints-dr-michael-secora-as-chief-financial-officer https://recursion.com/news/recursion-appoints-dr-ramona-doyle-as-chief-medical-officer https://recursion.com/news/recursion-appoints-dr-shafique-virani-as-chief-corporate-development-officer https://recursion.com/news/recursion-appoints-jordan-christensen-as-vice-president-of-engineering https://recursion.com/news/recursion-appoints-louisa-daniels-as-chief-legal-officer-and-general-counsel https://recursion.com/news/recursion-at-jpm-exscientia-merger-and-the-coming-virtual-cell https://recursion.com/news/recursion-ceo-biotechs-rainy-season-is-not-over----but-we-must-race-ahead https://recursion.com/news/recursion-ceo-chris-gibson-on-accelerating-the-biopharmaceutical-industry-with-ai https://recursion.com/news/recursion-ceo-chris-gibson-talks-integrating-ai-into-drug-development-process https://recursion.com/news/recursion-ceo-chris-gibson-theres-real-opportunity-to-leverage-a-i-to-speed-up-drug-development https://recursion.com/news/recursion-ceo-on-688m-exscientia-acquisition-hope-to-bring-better-medicines-to-patients-sooner https://recursion.com/news/recursion-ceo-publicly-funded-research-built-the-biopharma-industry-now-it-needs-our-help https://recursion.com/news/recursion-completes-supercomputer-for-ai-drug-discovery https://recursion.com/news/recursion-developer-experience-evaluating-python-dependency-managers https://recursion.com/news/recursion-enhances-its-leadership-team-and-deepens-focus-on-neuroscience-with-three-senior-appointments https://recursion.com/news/recursion-gets-fda-approval-to-begin-phase-1-trials-of-ai-discovered-cancer-treatment https://recursion.com/news/recursion-initiates-two-additional-clinical-trials-for-a-total-of-four-in-2022 https://recursion.com/news/recursion-is-granted-eu-orphan-drug-designation-for-rec-4881-for-the-potential-treatment-of-familial-adenomatous-polyposis https://recursion.com/news/recursion-is-granted-fda-fast-track-designation-for-rec-2282-for-the-potential-treatment-of-nf2-mutated-meningiomas https://recursion.com/news/recursion-is-granted-orphan-drug-designation-for-rec-4881-for-the-potential-treatment-of-familial-adenomatous-polyposis https://recursion.com/news/recursion-mit-ai-screens-thousands-of-molecules-before-a-single-fep-run-completes https://recursion.com/news/recursion-opens-child-care-center-to-support-employees https://recursion.com/news/recursion-partners-with-nvidia-in-groundbreaking-collaboration https://recursion.com/news/recursion-partners-with-nvidia-to-unveil-phenom-beta-democratizing-access-to-its-1-billion-phenomics-investment https://recursion.com/news/recursion-pharma-sharpens-oncology-focus-with-potential-1-5b-bayer-collaboration https://recursion.com/news/recursion-pharmaceuticals-announces-closing-of-initial-public-offering https://recursion.com/news/recursion-pharmaceuticals-announces-pricing-of-initial-public-offering https://recursion.com/news/recursion-pharmaceuticals-has-a-prescription-for-high-drug-costs-ai-and-25-petabytes-of-data https://recursion.com/news/recursion-pharmaceuticals-puts-strength-on-full-display https://recursion.com/news/recursion-pharmaceuticals-raises-239-million-and-partners-with-bayer-for-ai-drug-discovery https://recursion.com/news/recursion-pharmaceuticals-wants-to-4x-its-supercomputing-power-for-ai-with-the-help-of-nvidia-heres-why-it-matters https://recursion.com/news/recursion-pharmas-ai-powered-therapy-reduces-polyp-growth-in-a-rare-disease-trial https://recursion.com/news/recursion-policies-and-practices-that-attract-retain-and-advance-women https://recursion.com/news/recursion-posts-immune-mapping-and-drug-discovery-resource-and-releases-new-image-datasets https://recursion.com/news/recursion-provides-business-updates-and-reports-first-quarter-2022-financial-results https://recursion.com/news/recursion-provides-business-updates-and-reports-fourth-quarter-and-fiscal-year-2021-financial-results https://recursion.com/news/recursion-provides-business-updates-and-reports-second-quarter-2022-financial-results https://recursion.com/news/recursion-provides-business-updates-and-reports-third-quarter-2021-financials https://recursion.com/news/recursion-provides-updated-guidance-on-clinical-trial-starts https://recursion.com/news/recursion-publishes-first-environmental-social-and-governance-esg-report https://recursion.com/news/recursion-receives-iss-esg-prime-rating-and-plans-to-participate-in-the-goldman-sachs-global-sustainability-forum https://recursion.com/news/recursion-releases-molrec-a-compound-intelligence-tool-for-drug-discovery-alongside-the-largest-of-its-kind-open-source-dataset-during-first-r-d-day https://recursion.com/news/recursion-reports-first-quarter-2021-financials-and-provides-business-updates https://recursion.com/news/recursion-reports-second-quarter-2021-financials-and-provides-business-updates https://recursion.com/news/recursion-screens-protein-small-molecule-interactions-at-vast-scale https://recursion.com/news/recursion-shares-perspectives-with-fda-on-using-ai-and-ml-in-drug-discovery-and-development https://recursion.com/news/recursion-signs-lease-with-vestar-for-an-additional-100-000-sf-of-space-at-the-gateway-in-downtown-salt-lake-city https://recursion.com/news/recursion-thinks-ai-can-lower-the-high-failure-rate-of-new-pharmaceutical-drugs https://recursion.com/news/recursion-to-acquire-exscientia-combining-ai-drug-pioneers https://recursion.com/news/recursion-to-buy-ai-rival-exscientia https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conference https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conference-8 https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conference-f https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conferences https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conferences-1 https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conferences-3 https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conferences-30 https://recursion.com/news/recursion-to-participate-in-upcoming-investor-conferences-8 https://recursion.com/news/recursion-winter-break https://recursion.com/news/recursions-fast-track-road-to-therapeutics-using-ai-based-maps-of-biology https://recursion.com/news/recursions-incoming-ceo-on-turning-ai-drugs-into-clinical-proof-points https://recursion.com/news/recursions-najat-khan-ai-will-be-judged-by-the-medicines-it-delivers https://recursion.com/news/rising-leaders-2025-daniel-cohens-transition-from-grad-to-ai-pioneer-in-drug-discovery https://recursion.com/news/risk-mitigation-in-target-assessment-chemical-and-structural-approaches-to-chemical-tractability https://recursion.com/news/roche-signs-machine-learning-neuroscience-deal-with-recursion https://recursion.com/news/rxrx19 https://recursion.com/news/rxrx3-core-benchmarking-drug-target-interactions-in-high-content-microscopy https://recursion.com/news/rxrx3-phenomics-map-of-biology https://recursion.com/news/sending-the-ladder-down-while-still-climbing https://recursion.com/news/series-d https://recursion.com/news/sf-healthcare-week-recursions-new-ceo-najat-khan-shares-her-vision-for-the-company-and-for-ai-in-biotech https://recursion.com/news/since-its-inception-recursion-has-been-building-the-foundation-for-the-first-virtual-cell https://recursion.com/news/technology-is-crucial-in-driving-our-success-a-q-a-with-lina-nilsson-phd-chief-platform-officer-at-recursion https://recursion.com/news/testing-the-limits-of-smiles-based-de-novo-molecular-generation-with-curriculum-and-deep-reinforcement-learning https://recursion.com/news/the-10-most-innovative-biotech-companies-of-2023 https://recursion.com/news/the-8-leading-biotechs-using-ai-to-upend-how-drugs-are-discovered https://recursion.com/news/the-ceo-of-a-1-6-billion-biotech-says-his-bet-on-ai-is-paying-off-with-faster-cheaper-research-that-could-reshape-the-industry https://recursion.com/news/the-intersection-of-tech-and-biotech-with-chris-gibson https://recursion.com/news/the-netflix-of-digital-biology-recursion-is-reimagining-drug-discovery https://recursion.com/news/the-quest-for-better-protein-ligand-interaction-modeling---improving-ml-methods-offer-promise-for-ai-drug-discovery https://recursion.com/news/the-spark-for-decoding-biology-an-origin-story https://recursion.com/news/trans-atlantic-triumph-ai-drug-pioneers-recursion-exscientia-combine https://recursion.com/news/trillion-dollar-partner-recursion-raises-50m-from-nvidia-stock-skyrockets https://recursion.com/news/tupelo-trial-a-phase-2-multicenter-randomized-double-blind-placebo-controlled-trial-to-evaluate-efficacy-safety-pharmacokinetics-and-pharmacodynamics-of-rec-4881-in-subjects-with-familial-adenomatous-polyposis-fap-study-design https://recursion.com/news/two-exciting-recursion-oncology-programs-highlighted-at-aacr-2023-conference https://recursion.com/news/txpert-using-multiple-knowledge-graphs-for-prediction-of-transcriptomic-perturbation-effects https://recursion.com/news/uncovering-how-biology-works https://recursion.com/news/using-ai-and-automation-to-improve-outcomes-in-infectious-diseases https://recursion.com/news/using-llms-for-faster-answers-to-deeper-biological-questions-for-drug-discovery-research https://recursion.com/news/vitally-consistent-scaling-biological-representation-learning-for-cell-microscopy https://recursion.com/news/voici-le-frenchsicle-une-rafraichissante-sucette-glacee-au-ketchup-de-french-smd-offerte-pour-une-periode-limitee https://recursion.com/news/we-look-like-what-the-future-of-all-biopharma-companies-will-look-like-says-recursion-ceo-gibson https://recursion.com/news/what-i-learned-changing-industries-from-petroleum-to-biotech https://recursion.com/news/where-are-all-the-ai-drugs https://recursion.com/news/wilds-a-benchmark-of-in-the-wild-distribution-shifts https://recursion.com/news/will-ai-ever-cure-cancer-the-multibillion-dollar-race-to-bring-the-first-ai-discovered-drug-to-market